title: The intriguing future of pharmacoepidemiology.
abstract: Over the years more and more data have become available in the constantly growing databases on prescription drugs. This has facilitated the development of pharmacoepidemiology, a dynamic research field that has undergone a more rapid development than many other research areas. There are several reasons why pharmacoepidemiology will remain recognized as one of the most dynamic and challenging research areas of clinical pharmacology. The data explosion in modern society will continue, and observational studies aimed at assessing the value of medicines will be increasingly requested by payers, professionals and patients. Future studies in pharmacoepidemiology must include specialist drugs used in the hospital setting and also be designed to address obstacles hindering the delivery of effective medicines to the patient. Pharmacoepidemiological methods may also be valuable tools to address new challenges, such as the environmental impact of medicines. A potential threat is that the increasing amounts of data available in registries may add fuel to the debate on confidentiality. The too strict application of privacy rules might hinder the further development of pharmacoepidemiology.
authors: Karolinska Institutet, Centre for Pharmacoepidemiology, Department of Medicine, Clinical Epidemiology Unit T2, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. bjorn.wettermark@ki.se
authors: Björn
authors: B
authors: Wettermark
mesh_terms: D015982:Bias; D015986:Confounding Factors, Epidemiologic; D004363:Drug Utilization; D006801:Humans; D017891:Pharmacoepidemiology; D010601:Pharmacology, Clinical
references: Eur J Clin Pharmacol. 2012 Feb;68(2):123-9
references: 21808989
references: Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-94
references: 19961477
references: Eur J Clin Pharmacol. 1975 Feb 28;8(2):83-9
references: 1233211
references: Br J Clin Pharmacol. 1986;22 Suppl 1:55S-59S
references: 3567033
references: Clin Pharmacol Ther. 2007 Aug;82(2):143-56
references: 17554243
references: Eur J Clin Pharmacol. 1985;29(1):1-8
references: 4054197
references: Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):465-76
references: 15651087
references: J Chronic Dis. 1969 Dec;22(6):395-405
references: 5370512
references: J Clin Epidemiol. 1991;44(8):823-30
references: 1941035
references: Eur J Clin Pharmacol. 2011 May;67 Suppl 1:67-74
references: 21107830
references: Eur J Clin Pharmacol. 1986;30(5):521-5
references: 3758139
references: Int J Epidemiol. 1996 Apr;25(2):435-42
references: 9119571
references: Eur J Clin Pharmacol. 1986;30(5):513-9
references: 3530780
references: Br J Clin Pharmacol. 1998 May;45(5):419-25
references: 9643612
references: Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):260-5
references: 16611200
references: Br J Clin Pharmacol. 1999 Jan;47(1):105-10
references: 10073747
references: Int J Clin Pract. 2008 Jan;62(1):76-87
references: 17983433
references: Lancet. 2004 May 22;363(9422):1660-1
references: 15158623
references: Pharmacotherapy. 2009 Feb;29(2):138-53
references: 19170584
references: Drug Saf. 1995 Jul;13(1):1-7
references: 8527015
references: Br J Clin Pharmacol. 1983 Sep;16(3):301-4
references: 6626422
references: Epidemiology. 1996 Jul;7(4):335-6
references: 8793355
references: J Clin Epidemiol. 2005 Apr;58(4):323-37
references: 15862718
references: Basic Clin Pharmacol Toxicol. 2013 Jan;112(1):13-8
references: 22901097
references: Stat Methods Med Res. 2009 Feb;18(1):3-6
references: 19155246
references: Nat Rev Drug Discov. 2011 Jul 01;10(7):495-506
references: 21720406
references: Environ Health. 2007 Jul 24;6:20
references: 17650313
references: Ann Intern Med. 1990 Aug 1;113(3):179-81
references: 2197907
references: BMC Res Notes. 2012 Oct 16;5:570
references: 23069208